Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke

Laborértékek

• 1. Planning to receive endovascular therapy;
  • mRS scores ≥2 points before the onset;
  • Receiving any antiplatelet therapy after the onset;
  • Bleeding or other pathological brain disorders, such as vascular malformations, tumors, abscesses, or other common non-ischemic brain diseases (such as multiple sclerosis), identified by CT/MRI;
  • Pre-existing clotting disorders, systemic bleeding, thrombocytopenia, or neutropenia;
  • Pre-existing atrial fibrillation or anticoagulant therapy (warfarin, heparin, thrombin inhibitors or factor Xa inhibitors);
  • Hepatic or renal insufficiency (hepatic insufficiency refers to the alanine transaminase (ALT) value > 2 times the upper limit of normal value or aspartate aminotransferase (AST) times > 2 times the upper limit of normal value; renal insufficiency refers to creatinine values > 2 times the upper limit of normal value);
  • Allergic to Ticagrelor or Aspirin or thier components and excipients;
  • Women who are pregnant or breastfeeding, or those with negative pregnancy test records while refusing to use effective contraceptives;
  • Having participated investigational drugs or device tests within 30 days;
  • Being considered inappropriate to participate by researchers.

• 1. 18-80 years old;
  • Clinical diagnosis of acute ischemic stroke;
  • Time from onset to treatment ≤6.0 hours;
  • Having received or planning to receive intravenous thrombolytic therapy;
  • NIHSS score of 4-10 points, and at least one of the 5th (upper limb exercise) or 6 th (lower limb exercise) scale is ≥1 point;
  • Signed informed consent.